Q-omics provides the consensus-scored VCX3A profile across patient tissues and cancer cell-line models. VCX3A expression is associated with patient survival in 17 of 34 cancer types, with the highest sampling consensus in SCLC. Among the 18 cancer types available for tumor–normal comparison, VCX3A is differentially expressed in 7, with the highest sampling consensus in LUSC. Additionally, VCX3A RNA expression shows 6,507 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight SCLC, LUSC, and TGCT as cancer lineages where VCX3A shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for VCX3A — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes VCX3A survival associations across molecular data types. VCX3A RNA expression shows survival associations in the most cancer types (17), followed by mutation status (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible VCX3A RNA expression–survival associations across cancer types. High VCX3A expression shows unfavorable associations in COAD, KIRC, LIHC and LGG, but favorable associations in SCLC and SKCM. The SCLC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify SCLC as the clearest survival context for VCX3A RNA expression.
This table summarizes VCX3A tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 7. The strongest signals are observed in LUSC for RNA.
This table ranks reproducible tumor–normal expression differences for VCX3A. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. VCX3A shows higher tumor expression in LUSC, KICH, LIHC, HNSC, KIRP and STAD. The LUSC box plot shows higher VCX3A RNA expression in tumor versus normal tissue (log2 FC = +0.300, t-test p < 0.001).
This table shows molecular features associated with VCX3A in patient tissues and cancer cell lines. In patient samples, VCX3A shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, VCX3A RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SKIN, while CRISPR and shRNA rows add functional-dependency signals in LIVER.
